Volume 28, Issue 4 e14786
ORIGINAL ARTICLE

Safety and infectious outcomes in pediatric kidney transplant recipients after COVID-19 vaccination: A pediatric nephrology research consortium study

Travis Churilla

Corresponding Author

Travis Churilla

Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA

Correspondence

Travis Churilla, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.

Email: [email protected]

Search for more papers by this author
Clarkson Crane

Clarkson Crane

Division of Pediatric Nephrology, University of California San Diego, San Diego, California, USA

Search for more papers by this author
Rajasree Sreedharan

Rajasree Sreedharan

Division of Pediatric Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Search for more papers by this author
Bakri J. Alzarka

Bakri J. Alzarka

Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
Olga Charnaya

Olga Charnaya

Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, USA

Search for more papers by this author
Namrata G. Jain

Namrata G. Jain

Division of Pediatric Nephrology, Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, USA

Search for more papers by this author
Helen Pizzo

Helen Pizzo

Division of Pediatric Nephrology, Cedars-Sinai Medical Center, Los Angeles, California, USA

Search for more papers by this author
Asifhusen Mansuri

Asifhusen Mansuri

Children's Hospital of Georgia, Augusta University, Augusta, Georgia, USA

Search for more papers by this author
Amrish Jain

Amrish Jain

Division of Pediatric Nephrology, Children's Hospital of Michigan, Central Michigan University, Detroit, Michigan, USA

Search for more papers by this author
Manpreet Grewal

Manpreet Grewal

Division of Pediatric Nephrology, Children's Hospital of Michigan, Central Michigan University, Detroit, Michigan, USA

Search for more papers by this author
Joseph D. Fishbein

Joseph D. Fishbein

Division of Nephrology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA

Search for more papers by this author
Alexander J. Kula

Alexander J. Kula

Division of Nephrology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA

Search for more papers by this author
Taylor Heald-Sargent

Taylor Heald-Sargent

Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA

Search for more papers by this author
Debora Matossian

Debora Matossian

Division of Nephrology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA

Search for more papers by this author
Priya S. Verghese

Priya S. Verghese

Division of Nephrology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA

Search for more papers by this author
First published: 20 May 2024
Citations: 1

Abstract

Background

Adult kidney transplant recipients (KTRs) fully vaccinated against COVID-19 have substantial morbidity and mortality related to SARS-CoV-2 infection compared with the general population. However, little is known regarding the safety and efficacy of the COVID-19 vaccination series in pediatric KTRs.

Methods

A multicenter, retrospective observational study was performed across nine pediatric transplantation centers. Eligible KTRs fully vaccinated against COVID-19 were enrolled and data were collected pertaining to SARS-CoV-2 infection incidence and severity, graft outcomes and post-vaccination safety profile, as well as overall patient survival.

Results

A total of 247 patients were included in this investigation with a median age at transplantation of 11 years (IQR 5–15). SARS-CoV-2 infection was observed in 30/110 (27.27%) of fully vaccinated patients, tested post-transplant, within the defined follow-up period. Of these patients, 6/30 (18.18%) required hospitalization and 3/30 (12.12%) required reduction in immunosuppression, with no reported deaths. De novo donor-specific antibodies (DSAs) were found in 8/86 (9.30%) of DSA-tested patients with two experiencing rejection and subsequent graft loss. The overall incidence of rejection and graft loss among the total cohort was 11/247 (4.45%) and 6/247 (3.64%), respectively. A 100% patient survival was observed.

Conclusions

Observationally, infectious outcomes of SARS-CoV-2 in fully vaccinated pediatric KTRs are excellent, with a low incidence of infection requiring hospitalization and no associated deaths. Though de novo DSAs were observed, there was minimal graft rejection and graft loss reported in the total cohort.

CONFLICT OF INTEREST STATEMENT

Dr. Clarkson Crane is supported by the PIRCHE, AG – Fellowship Research Support Grant. All other authors for this study have no conflicts of interest or financial disclosures relevant to this investigation.

DATA AVAILABILITY STATEMENT

Research data is not shared.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.